These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 16277716

  • 1. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dünser MW.
    Crit Care; 2005 Oct 05; 9(5):R541-8. PubMed ID: 16277716
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.
    Crit Care Med; 2003 May 05; 31(5):1405-9. PubMed ID: 12771610
    [Abstract] [Full Text] [Related]

  • 3. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M, Canadian Critical Care Trials Group.
    Arch Intern Med; 2008 Sep 08; 168(16):1805-12. PubMed ID: 18779469
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR.
    J Crit Care; 2011 Aug 08; 26(4):347-51. PubMed ID: 21454037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H, Faraklas I, Saffle J, Cochran A.
    J Trauma; 2011 Dec 08; 71(6):1557-61. PubMed ID: 22027887
    [Abstract] [Full Text] [Related]

  • 11. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y.
    Thromb Haemost; 1995 Nov 08; 74(5):1286-92. PubMed ID: 8607111
    [Abstract] [Full Text] [Related]

  • 12. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.
    Mayr AJ, Dünser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W.
    Thromb Res; 2002 Feb 01; 105(3):201-4. PubMed ID: 11927124
    [Abstract] [Full Text] [Related]

  • 13. No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass.
    Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, Martin LF.
    Surg Obes Relat Dis; 2007 Feb 01; 3(4):469-75. PubMed ID: 17567541
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
    Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M, De Paoli M, Zanardi A, Palareti G.
    Thromb Res; 2009 Dec 01; 124(6):667-71. PubMed ID: 19482341
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L, Villatoro AJ, Monreal M, Espada Y, Anglés AM, Ruiz-Gopegui R.
    Am J Vet Res; 1995 Oct 01; 56(10):1281-5. PubMed ID: 8928943
    [Abstract] [Full Text] [Related]

  • 17. Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism.
    Yogaratnam D, Smith BS, Angood PB, Gandhi PJ.
    Pharmacotherapy; 2004 Dec 01; 24(12):1793-9. PubMed ID: 15585445
    [Abstract] [Full Text] [Related]

  • 18. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
    Haas S, Wolf H, Kakkar AK, Fareed J, Encke A.
    Thromb Haemost; 2005 Oct 01; 94(4):814-9. PubMed ID: 16270636
    [Abstract] [Full Text] [Related]

  • 19. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL, Bungard TJ.
    Pharmacotherapy; 2006 Oct 01; 26(10):1479-90. PubMed ID: 16999658
    [Abstract] [Full Text] [Related]

  • 20. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
    Lachish T, Rudensky B, Slotki I, Zevin S.
    Pharmacotherapy; 2007 Oct 01; 27(10):1347-52. PubMed ID: 17896889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.